Kamada to report Q2 and H1 2026 results August 12

Rhea-AI Filing Summary

Kamada Ltd., a global biopharmaceutical company focused on specialty plasma-derived therapies for rare and serious conditions, stated it will release financial results for the second quarter and first half ended June 30, 2026 before U.S. market open on Wednesday, August 12, 2026. Management will hold an investment community conference call at 8:30am Eastern Time that day, accessible via U.S., Israel, and international dial-in numbers and a live webcast.

The company describes a growth strategy built on four pillars: organic expansion of a commercial portfolio that includes six FDA-approved specialty plasma-derived products plus additional hyper-immune and anti-snake venom therapies; distribution of third-party pharmaceuticals and biosimilars in Israel and the MENA region through in-licensing partnerships; ramp-up of plasma collection operations via three FDA-approved U.S. plasma collection centers; and pursuit of mergers, acquisitions, in-licensing and collaborations to enhance its marketed portfolio. FIMI Opportunity Funds is identified as the controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.

Filing Explained

The Form 6-K incorporates its August 5 announcement by reference into six Form S-8 registration statements, extending that filing content to those registration documents; it does not disclose that shares were offered or issued.

Key Figures

Results release date: August 12, 2026 Controlling shareholder ownership: approximately 38% of the outstanding ordinary shares FDA-approved products: six FDA-approved specialty plasma-derived products +2 more

5 metrics

Results release date August 12, 2026 Planned release date for Q2 and first-half 2026 financial results

Controlling shareholder ownership approximately 38% of the outstanding ordinary shares FIMI Opportunity Funds beneficial ownership stake in Kamada

FDA-approved products six FDA-approved specialty plasma-derived products Number of proprietary specialty plasma-derived products in Kamada’s commercial portfolio

Plasma collection centers three FDA-approved operating plasma collection centers in the United States Owned centers located in Beaumont, Houston, and San Antonio, Texas

Conference call time 8:30am Eastern Time Scheduled time of the August 12, 2026 investment community conference call

Key Terms

specialty plasma-derived therapies, hyper-immune plasma, in-licensing partnerships, beneficially owning, +1 more

5 terms

specialty plasma-derived therapies medical

"a leader in the specialty plasma-derived therapies field"

hyper-immune plasma medical

"to support its increasing demand for hyper-immune plasma"

in-licensing partnerships financial

"distribution of third-parties’ pharmaceutical products... through in-licensing partnerships"

beneficially owning financial

"beneficially owning approximately 38% of the outstanding ordinary shares"

Beneficially owning a security means you have the economic rights and practical power over shares even if they’re held in another name—you can receive dividends, sell the shares, or direct how they’re voted. Think of it like renting a car: you may not hold the title, but you control and use it. For investors, beneficial ownership reveals who actually controls or benefits from a company’s stock and is used in regulatory disclosure and voting calculations.

biosimilar products medical

"including the launch of several biosimilar products in Israel"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Kamada (KMDA) report its Q2 and first-half 2026 financial results?

Kamada plans to release Q2 and first-half 2026 financial results before U.S. markets open on Wednesday, August 12, 2026. The period covered is the quarter and first half ended June 30, 2026, followed by a conference call that same morning.

What time is Kamada’s (KMDA) Q2 2026 conference call and how can investors join?

Kamada’s investment community conference call is scheduled for 8:30am Eastern Time on August 12, 2026. Participants can dial 1-877-407-0792 (U.S.), 1-809-406-247 (Israel), or 1-201-689-8263 (international), or listen via a live webcast at the provided URL.

What is Kamada’s (KMDA) core business focus?

Kamada is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions. Its portfolio includes six FDA-approved plasma-derived products, additional hyper-immune therapies, and equine-based anti-snake venom products, supported by in-house manufacturing and R&D capabilities.

Who is the controlling shareholder of Kamada (KMDA) and what stake do they hold?

FIMI Opportunity Funds is identified as Kamada’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. FIMI is described as the leading private equity firm in Israel and holds this significant ownership position in the company.

How is Kamada (KMDA) expanding its plasma collection operations?

Kamada is ramping up plasma collection operations by owning three FDA-approved operating plasma collection centers in Beaumont, Houston, and San Antonio, Texas. These centers support sales of normal source plasma to other manufacturers and meet rising demand for hyper-immune plasma for its products.

What are the main growth pillars in Kamada’s (KMDA) business strategy?

Kamada’s strategy emphasizes four pillars: organic growth of its proprietary plasma-derived portfolio; distribution of third-party drugs and biosimilars in Israel and MENA via in-licensing; expansion of plasma collection operations; and pursuit of M&A, in-licensing, and collaborations to enhance its marketed portfolio.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 07:00 AM Accepted by SEC EDGAR 08/05/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the Month of August 2026

Commission File Number 001-35948

Kamada Ltd.

(Translation of registrant’s name into English)

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

The following exhibit is attached:

99.1 Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 5, 2026	KAMADA LTD.
	By:	/s/ Nir Livneh
		Nir Livneh Vice President General Counsel and Corporate Secretary

2

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

3

Exhibit 99.1

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

Company to Host Conference Call at 8:30am ET

REHOVOT, Israel, and HOBOKEN, NJ – August 5, 2026 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that it will release financial results for the second quarter and first half ended June 30, 2026, prior to the open of the U.S. financial markets on Wednesday, August 12, 2026.

Kamada management will host an investment community conference call on Wednesday, August 12, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13761830. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1770235&tp_key=a29c72f53b.

About Kamada

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third-parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

CONTACTS:

Chaime Orlev

Chief Financial Officer

IR@kamada.com

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

britchie@LifeSciAdvisors.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 KAMADA TO ANNOUNCE SECOND QUARTER AND FIRST HALF ENDED JUNE 30, 2026 FINANCIAL R 6.0 KB